Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Autor: Zorrilla, CD, Wright, R, Osiyemi, OO, Yasin, S, Baugh, B, Brown, K, Coate, B, Verboven, P, Mrus, J, Falcon, R, Kakuda, TN

Publikováno v: HIV Medicine; Jan2014, Vol. 15 Issue 1, p50-56, 7p

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Autor: Mills AM; Men's Health Foundation, Los Angeles, CA, USA., Rizzardini G; Hospital Sacco, Milan, Italy; School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa., Ramgopal MN; Midway Immunology and Research Center, Fort Pierce, FL, USA., Osiyemi OO; Triple O Research Institute, West Palm Beach, FL, USA., Bogner JR; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Hagins DP; Chatham County Health Department, Savannah, Georgia, USA., Paredes R; Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; IrsiCaixa AIDS Research Institute, Badalona, Spain; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Reynes J; Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France; TransVIHMI, University of Montpellier, IRD, INSERM, Montpellier, France., Rockstroh JK; Department of Medicine I, University of Bonn, Bonn, Germany., Carr A; Immunology and HIV Unit, St Vincent's Hospital, Sydney, NSW, Australia., Su FH; Merck & Co, Rahway, NJ, USA., Klopfer SO; Merck & Co, Rahway, NJ, USA., Eves K; Merck & Co, Rahway, NJ, USA., Plank RM; Merck & Co, Rahway, NJ, USA., Correll T; Merck & Co, Rahway, NJ, USA., Fox MC; Merck & Co, Rahway, NJ, USA. Electronic address: michelle.fox2@merck.com.

Publikováno v: The lancet. HIV [Lancet HIV] 2024 Jun; Vol. 11 (6), pp. e357-e368. Date of Electronic Publication: 2024 May 08.

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

Autor: DeJesus E; Orlando Immunology Center, Orlando, FL, USA. edejesus@oicorlando.com, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J

Publikováno v: Antiviral therapy [Antivir Ther] 2010; Vol. 15 (5), pp. 711-20.